<DOC>
	<DOCNO>NCT01789840</DOCNO>
	<brief_summary>The purpose study evaluate improvement symptom benign prostatic hyperplasia ( BPH ) assess International Prostate Symptom Score ( IPSS ) prostatic artery embolization ( PAE ) use Embosphere Microspheres compare conventional transurethral resection prostate ( TURP ) .</brief_summary>
	<brief_title>Prostate Artery Embolization With Embosphere Microspheres Compared TURP Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>1 . Patient age 50 79 , inclusive 2 . Patient sign informed consent 3 . Patient low urinary tract symptom ( LUTS ) secondary BPH least 6 month prior study treatment 4 . Patient baseline IPSS Score &gt; 13 baseline 5 . Patient prostate size least 50 gram 90 gram , measure MRI 6 . Patient BPH symptom refractory medical treatment medication contraindicate , tolerate refuse 7 . Patient must candidate TURP 8 . Patient must meet ONE follow criterion : Baseline Prostate Specific Antigen ( PSA ) &lt; 2.5 ng/mL ( prostate biopsy require ) Baseline PSA &gt; 2.5 ng/mL ≤10 ng/mL AND free PSA &gt; 25 % total PSA ( prostate biopsy require ) Baseline PSA &gt; 2.5 ng/mL ≤10 ng/mL AND free PSA &lt; 25 % total PSA AND negative prostate biopsy result ( minimum 12 core biopsy ) Baseline PSA &gt; 10 ng/mL AND negative prostate biopsy ( minimum 12 core biopsy ) 1 . Active urinary tract infection 2 . Biopsy proven prostate bladder cancer , cancer basal squamous cell skin cancer The following patient must undergo prostate biopsy minimum 12 core negative histopathology report enrol study : Patients digital rectal examination ( DRE ) find suspicious prostate cancer Patients baseline PSA level &gt; 10 ng/mL Patients baseline PSA level &gt; 2.5 ng/mL &lt; 10ng/mL AND free PSA &lt; 25 % total PSA Patients cystoscopy finding suspicious bladder cancer must undergo biopsy negative histopathology report enrol study 3 . Bladder atonia , neurogenic bladder disorder neurological disorder impact bladder function ( eg multiple sclerosis , Parkinson 's disease , spinal cord injury , etc ) 4 . Urethral stricture , bladder neck contracture , sphincter abnormality , urinary obstruction due cause BPH , potentially confound bladder urethral disease condition 5 . Patient take beta blocker , antihistamine , anticonvulsant , antispasmodic within 1 week study treatment AND drug dosage 6 month stable void pattern • Dosage medication change study participation unless medically necessary 6 . Patient take antidepressant , anticholinergic , androgen gonadotropinreleasing hormonal analogue within 2 month study treatment AND drug dosage least 3 month stable void pattern 7 . Patient take 5alpha reductase inhibitor alpha blocker within 1 month study treatment AND drug dosage least 3 month stable void pattern 8 . Previous nonmedical BPH treatment , include surgery , TURP , needle ablation , microwave laser therapy , balloon dilation , stent implantation , invasive treatment prostate 9 . Any known condition limit catheterbased intervention contraindication embolization , intolerance vessel occlusion procedure severe atherosclerosis . 10 . Patient unable stop taking anticoagulant , nonsteroidal antiinflammatory drug ( NSAID ) antiplatelet therapy 7 day prior study treatment 11 . Unable MRI imaging ( eg metal implant include pacemaker , replacement joint , etc ) 12 . Patient asymmetric prostate , &gt; 20 % difference size lob 13 . Cardiac condition include congestive heart failure arrhythmia , uncontrolled diabetes mellitus , significant respiratory disease know immunosuppression require hospitalization within previous 6 month 14 . Baseline serum creatinine level &gt; 1.8 mg/dl 15 . Known upper tract renal disease 16 . Cystolithiasis chronic hematuria within 3 month prior study treatment 17 . Active prostatitis 18 . Previous rectal surgery hemorrhoidectomy , history rectal disease 19 . History pelvic irradiation radical pelvic surgery 20 . Patient interested future fertility 21 . Coagulation disturbance normalize medical treatment 22 . Acute urinary retention require indwell catheter 23 . Known major iliac arterial occlusive disease 24 . Allergy iodinate contrast agent 25 . Hypersensitivity gelatin product</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>BPH</keyword>
	<keyword>Prostate</keyword>
	<keyword>Prostatic Hyperplasia</keyword>
	<keyword>enlarge prostate</keyword>
	<keyword>LUTS</keyword>
	<keyword>urinary retention</keyword>
</DOC>